UBS Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy maintains a Neutral rating on Edwards Lifesciences (NYSE:EW) and lowers the price target from $90 to $75.
September 10, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS has maintained a Neutral rating on Edwards Lifesciences but lowered the price target from $90 to $75, indicating a more cautious outlook.
The lowering of the price target by UBS suggests a less optimistic view on Edwards Lifesciences' future performance, which could lead to a short-term negative impact on the stock price. The Neutral rating indicates no strong buy or sell recommendation, but the reduced price target reflects potential concerns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100